Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep

N. B. Singanallur, J. M. Pacheco, J. Arzt, C. Stenfeldt, G. T. Fosgate, L. Rodriguez, W. Vosloo

Research output: Contribution to journalArticlepeer-review

5 Scopus citations

Abstract

Potency tests for commercial oil-adjuvanted foot-and-mouth disease (FMD) vaccines are usually carried out in cattle, using a full dose (2 ml) of vaccine and homologous virus challenge. However, in sheep the recommended vaccine dose is half of the cattle dose (1 ml) and most vaccines have not been potency tested for this species, especially with heterologous viruses. To determine the efficacy of a high potency (>6PD50) FMD virus (FMDV) O1Manisa vaccine in sheep, we carried out a study using a heterologous FMDV (FMDV O/SKR/2010 - Mya-98 strain) challenge. Groups of seven animals each were vaccinated with 2×, 1×, 1/2× or 1/4× dose (2 ml, 1 ml, 0.5 ml or 0.25 ml respectively) and challenged at 7 days post vaccination (dpv). Only 3 of the 7 sheep in the group vaccinated with 2 ml were protected. With 2 additional groups, receiving double or single doses and challenged at 14 dpv, 4 of 7 sheep were protected in each group. None of the sheep had measurable neutralising antibodies against the vaccine or challenge virus at 7 dpv. However, all vaccinated animals challenged at 14 dpv had a homologous neutralising response against FMDV O1 Manisa on the day of challenge and all but one animal also had a heterologous response to FMDV O/SKR/2010. Infectious FMDV and viral RNA could be found in nasal swabs between 1 and 6 days post challenge (dpc) in most vaccinated sheep, but those vaccinated with higher doses or challenged at 14 dpv showed significant decreases in the level of FMDV detection. Intermittent virus shedding was noticed between 1 and 35 dpc in all vaccinated groups, but persistent infection could be demonstrated only in 4 sheep (20%). This study showed that at the recommended dose, a high potency (>6 PD50) FMDV O1Manisa vaccine does not protect sheep against a heterologous challenge at 7 dpv. However, partial protection was observed when a double dose was used at 7 dpv or when double or single dose vaccinated sheep were challenged at 14 dpv.

Original languageEnglish (US)
Pages (from-to)114-122
Number of pages9
JournalAntiviral Research
Volume145
DOIs
StatePublished - Sep 2017

Bibliographical note

Funding Information:
Funding was provided in part by the livestock industries in Australia through Animal Health Australia (AHA). The relevant industry bodies are the Cattle Council of Australia, Australian Dairy Farmers, Australian Lot Feeders Association, Wool Producers Australia, Sheepmeat Council of Australia, Australian Pork Limited and the Goat Industry Council of Australia. The AHA funds are matched through the Meat and Livestock Australia Donor Company by the Australian Government under MLA Project P.PSH 0652. This work was also supported in part by USDA, Agricultural Research Service (ARS) (CRIS 1940-32000-057-00D). CS was recipient of a PIADC Research Participation Program fellowship administered by Oak Ridge Institute for Science and Education (ORISE) through an interagency agreement with the US Department of Energy. We also acknowledge the technical support provided by Mr Ethan J. Hartwig and Mr George R. Smoliga.

Publisher Copyright:
© 2017 Elsevier B.V.

Keywords

  • Dose response
  • Foot and mouth disease virus
  • Heterologous challenge
  • Sheep
  • Vaccine efficacy

Fingerprint

Dive into the research topics of 'Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep'. Together they form a unique fingerprint.

Cite this